Ifosfamide induced encephalopathy in a child with osteosarcoma

Area of Science:

• Oncology
• Neuroscience
• Pharmacology

Background:

• Ifosfamide (IFO) is a crucial alkylating agent for treating various malignancies.
• Neurotoxicity is a significant, yet reversible, adverse effect of IFO therapy.
• Ifosfamide-induced encephalopathy (IIE) is a rare but serious complication.

Observation:

• A pediatric osteosarcoma patient developed neurological symptoms after 20 weeks of IFO treatment.
• Initial laboratory and imaging studies did not reveal the cause of neurological decline.
• Electroencephalography indicated neuronal hyperexcitability, leading to the diagnosis of IIE.

Findings:

• Prompt diagnosis of IIE was established in a pediatric osteosarcoma patient.
• Methylene blue prophylaxis was administered before subsequent IFO infusions.
• Neurological symptoms resolved, and treatment continuation was successful.

Implications:

• IIE is a manageable complication, allowing for the continuation of essential chemotherapy.
• Methylene blue serves as an effective prophylactic agent against IFO-induced neurotoxicity.
• This case highlights the importance of recognizing and managing IIE in pediatric oncology.